Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2010

01.05.2010

Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction

verfasst von: Robin A. P. Weir, Sean Balmain, Tracey Steedman, Leong L. Ng, Iain B. Squire, Anne Rumley, Henry J. Dargie, Gordon D. O. Lowe

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Von Willebrand factor (VWF) and tissue plasminogen activator (t-PA) predict adverse cardiovascular outcome following acute myocardial infarction (AMI) and are weakly associated with pre-discharge left ventricular ejection fraction (LVEF). We examined the relationships between VWF, t-PA antigen, matrix metalloproteinase (MMP)-2,-3, and -9, and B-type natriuretic peptide (BNP), and their predictive effect on serial change in LV volumes in a cohort of patients admitted with AMI. Plasma VWF, t-PA antigen, MMP-2,-3,-9, and BNP were measured at a mean 46 h after AMI in 100 patients (mean age 58.9 ± 12 years, 77% male) with depressed LVEF. Cardiac magnetic resonance (CMR) imaging was then performed. Biomarker measurement and CMR were repeated at 12 and 24 weeks. Plasma concentrations of VWF, BNP and MMP-9 were elevated while t-PA antigen concentration was at the upper limits of normal; over 24 weeks VWF, t-PA antigen, MMP-9 and BNP decreased significantly. Baseline VWF correlated with BNP (r = 0.35, P < 0.001) and MMP-3 (r = 0.24, P = 0.019) as did t-PA antigen (r = 0.27, P = 0.007 for BNP; r = 0.40, P < 0.001 for MMP-3). t-PA antigen, VWF, MMP-3 and BNP were univariate predictors of LV end-systolic volume at 24 weeks; tPA antigen and BNP remained significant independent predictors on multivariate analysis. t-PA antigen and VWF are related to medium-term LV volumes after AMI, and to MMP-3. This novel link between the coagulation-fibrinolysis system and matrix turnover merits further study in understanding the pathophysiology of adverse ventricular remodeling after AMI.
Literatur
1.
Zurück zum Zitat Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH (2004) Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25(3):252–259CrossRefPubMed Lowe GD, Danesh J, Lewington S, Walker M, Lennon L, Thomson A, Rumley A, Whincup PH (2004) Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25(3):252–259CrossRefPubMed
2.
Zurück zum Zitat Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG (1996) Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group. European concerted action on thrombosis and disabilities. Circulation 94(9):2057–2063PubMed Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG (1996) Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT study group. European concerted action on thrombosis and disabilities. Circulation 94(9):2057–2063PubMed
3.
Zurück zum Zitat Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, Choussat R, Beygui F, Borentain M, Vignolles N, Thomas D (2003) Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108(4):391–394CrossRefPubMed Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, Choussat R, Beygui F, Borentain M, Vignolles N, Thomas D (2003) Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 108(4):391–394CrossRefPubMed
4.
Zurück zum Zitat Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D (1998) Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE trial. Circulation 98(4):294–299PubMed Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D (1998) Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE trial. Circulation 98(4):294–299PubMed
5.
Zurück zum Zitat Sosin MD, Bhatia G, Davis RC, Lip GY (2003) Congestive heart failure and Virchow’s triad: a neglected association. Wien Med Wochenschr 153(19–20):411–416CrossRefPubMed Sosin MD, Bhatia G, Davis RC, Lip GY (2003) Congestive heart failure and Virchow’s triad: a neglected association. Wien Med Wochenschr 153(19–20):411–416CrossRefPubMed
6.
Zurück zum Zitat El-Menyar AA, Altamimi OM, Gomaa MM, Dabdoob W, Abbas AA, Abdel Rahman MO, Bener A, Albinali HA (2006) Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction. Coron Artery Dis 17(5):431–437CrossRefPubMed El-Menyar AA, Altamimi OM, Gomaa MM, Dabdoob W, Abbas AA, Abdel Rahman MO, Bener A, Albinali HA (2006) Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction. Coron Artery Dis 17(5):431–437CrossRefPubMed
7.
Zurück zum Zitat Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA (1997) Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART study investigators. Circulation 96(2):442–447PubMed Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA (1997) Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART study investigators. Circulation 96(2):442–447PubMed
8.
Zurück zum Zitat Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17(4):439–444CrossRefPubMed Carmeliet P, Moons L, Lijnen R, Baes M, Lemaître V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 17(4):439–444CrossRefPubMed
9.
Zurück zum Zitat Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC (2005) N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 96(1):31–34CrossRefPubMed Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC (2005) N-terminal pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 96(1):31–34CrossRefPubMed
10.
Zurück zum Zitat Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ (2009) Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157(6):1088–1096CrossRefPubMed Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I, Ng LL, Squire IB, Wagner GS, McMurray JJ, Dargie HJ (2009) Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157(6):1088–1096CrossRefPubMed
11.
Zurück zum Zitat Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American heart association. Circulation 105(4):539–542CrossRefPubMed Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American heart association. Circulation 105(4):539–542CrossRefPubMed
12.
Zurück zum Zitat White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76(1):44–51PubMed White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76(1):44–51PubMed
13.
Zurück zum Zitat Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB (2008) Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10(2):133–139CrossRefPubMed Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB (2008) Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 10(2):133–139CrossRefPubMed
14.
Zurück zum Zitat Booth NA (1999) Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol 12(3):423–433PubMedCrossRef Booth NA (1999) Fibrinolysis and thrombosis. Baillieres Best Pract Res Clin Haematol 12(3):423–433PubMedCrossRef
15.
Zurück zum Zitat Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 332(10):635–641CrossRefPubMed Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 332(10):635–641CrossRefPubMed
16.
Zurück zum Zitat De Bono D (1994) Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 71(6):504–507CrossRefPubMed De Bono D (1994) Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease. Br Heart J 71(6):504–507CrossRefPubMed
17.
Zurück zum Zitat Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM, CADET Study Investigators (2004) A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2(11):1934–1940CrossRefPubMed Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM, CADET Study Investigators (2004) A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2(11):1934–1940CrossRefPubMed
18.
Zurück zum Zitat Jansson JH, Nilsson TK, Johnson O (1998) von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80(4):334–337PubMed Jansson JH, Nilsson TK, Johnson O (1998) von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80(4):334–337PubMed
19.
Zurück zum Zitat Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, Kojima T, Hirai M, Ito M, Loskutoff DJ, Saito H, Murohara T, Yamamoto K (2004) Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 164(2):449–456PubMed Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, Kojima T, Hirai M, Ito M, Loskutoff DJ, Saito H, Murohara T, Yamamoto K (2004) Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 164(2):449–456PubMed
20.
Zurück zum Zitat Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY (2003) Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 14(6):515–521CrossRefPubMed Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY (2003) Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis 14(6):515–521CrossRefPubMed
21.
Zurück zum Zitat Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY (2004) Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110(13):1794–1798CrossRefPubMed Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY (2004) Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110(13):1794–1798CrossRefPubMed
22.
Zurück zum Zitat Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GY (2006) Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97(5):671–675CrossRefPubMed Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GY (2006) Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 97(5):671–675CrossRefPubMed
23.
Zurück zum Zitat Pawłowska Z, Jerczyńska H, Szemraj J, Barańska P, Swiatkowska M, Cierniewski CS (2002) Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol Biol Lett 7(4):1153–1157PubMed Pawłowska Z, Jerczyńska H, Szemraj J, Barańska P, Swiatkowska M, Cierniewski CS (2002) Natriuretic peptides reduce plasminogen activator inhibitor-1 expression in human endothelial cells. Cell Mol Biol Lett 7(4):1153–1157PubMed
24.
Zurück zum Zitat Yoshizumi M, Tsuji H, Nishimura H, Masuda H, Kunieda Y, Kawano H, Kimura S, Sugano T, Kitamura H, Nakagawa K, Nakagawa M (1999) Natriuretic peptides regulate the expression of tissue factor and PAI-1 in endothelial cells. Thromb Haemost 82(5):1497–1503PubMed Yoshizumi M, Tsuji H, Nishimura H, Masuda H, Kunieda Y, Kawano H, Kimura S, Sugano T, Kitamura H, Nakagawa K, Nakagawa M (1999) Natriuretic peptides regulate the expression of tissue factor and PAI-1 in endothelial cells. Thromb Haemost 82(5):1497–1503PubMed
25.
Zurück zum Zitat de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345(14):1014–1021CrossRefPubMed de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345(14):1014–1021CrossRefPubMed
26.
Zurück zum Zitat Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG (2003) B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107(22):2786–2792CrossRefPubMed Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, Frampton C, Turner J, Crozier IG, Yandle TG (2003) B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107(22):2786–2792CrossRefPubMed
27.
Zurück zum Zitat Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, Daikoku S, Matsumoto T, Miyazaki S, Matsuoka H, Takishita S, Kangawa K, Matsuo H, Nonogi H (1998) Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135(1):21–28CrossRefPubMed Nagaya N, Nishikimi T, Goto Y, Miyao Y, Kobayashi Y, Morii I, Daikoku S, Matsumoto T, Miyazaki S, Matsuoka H, Takishita S, Kangawa K, Matsuo H, Nonogi H (1998) Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 135(1):21–28CrossRefPubMed
28.
Zurück zum Zitat Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM (2004) Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10(4):328–333CrossRefPubMed Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM (2004) Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10(4):328–333CrossRefPubMed
29.
Zurück zum Zitat Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28(6):711–718CrossRefPubMed Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28(6):711–718CrossRefPubMed
30.
Zurück zum Zitat Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59(4):812–823CrossRefPubMed Jones CB, Sane DC, Herrington DM (2003) Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59(4):812–823CrossRefPubMed
31.
Zurück zum Zitat Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC (2006) Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res 118(2):221–227CrossRefPubMed Tziakas DN, Chalikias GK, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris A, Hatseras DI, Kaski JC (2006) Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res 118(2):221–227CrossRefPubMed
32.
Zurück zum Zitat Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ (2000) Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2(4):271–278CrossRefPubMed Bellenger NG, Davies LC, Francis JM, Coats AJ, Pennell DJ (2000) Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2(4):271–278CrossRefPubMed
Metadaten
Titel
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction
verfasst von
Robin A. P. Weir
Sean Balmain
Tracey Steedman
Leong L. Ng
Iain B. Squire
Anne Rumley
Henry J. Dargie
Gordon D. O. Lowe
Publikationsdatum
01.05.2010
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2010
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-009-0383-6

Weitere Artikel der Ausgabe 4/2010

Journal of Thrombosis and Thrombolysis 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.